DNA Capital Consultoria, in its capacity as manager of investment funds, reported that, through the funds under its management, it now holds 601,708,118 common shares of Viveo (VVEO3), equivalent to approximately 47.03% of the company's total common shares, excluding treasury shares. The stake results from Viveo's capital increase, approved by the Board of Directors on October 30, 2026, and was disclosed to the market on November 6, 2026.
According to DNA Capital, the shares were subscribed during the preemptive rights exercise period and in the subscription of leftover shares (shares not subscribed by other shareholders). Payment was made upfront, in Brazilian currency, and also through the capitalization of credits from simple debentures, not convertible into shares, issued by Viveo and held by DNA Capital.
